Speciality Medicines Ltd...
SPEMEDSME
Ask IPO
Overview
Speciality Medicines Limited is engaged in the marketing and distribution of finished specialty pharmaceutical products. The company focuses on high-cost oral and injectable medications for complex and chronic conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. It operates through a dual business model: contract manufacturing of approved formulations for international distribution, and sourcing from manufacturers for marketing and distribution in domestic and international markets. Its diverse product portfolio includes various dosage forms such as tablets, capsules, injections, and syrups.
Opening Date
Mar 20, 2026
Closing Date
Mar 24, 2026
Listing Date
Mar 30, 2026
IPO Type
SME
IPO Status
Closed
Issue Size
—
Fresh Issue
29.14 Cr
Offer for Sale
0 Cr
Price Band
₹117 - ₹124
Lot Size
1000
IPO Timeline
Financials
Revenue
Profit After Tax (PAT)
IPO Objective
Our Company proposes to utilize the Net Proceeds from the Issue towards funding the following objects:
- •
Setting up a Research and Development (R&D) Centre in Valsad, Gujarat, to internalize formulation development, reduce reliance on third-party manufacturers, develop differentiated dosage forms, and shorten time-to-market for new products.
- •
Financing product registration in various international markets such as Ethiopia, Namibia, Jordan, and the Philippines, and funding product development and bioequivalence studies to expand presence in LATAM, Africa, and EMA markets.
- •
Funding marketing and promotional activities to enhance brand visibility, strengthen brand equity, and support sales growth across existing and emerging markets, including participation in global pharmaceutical exhibitions like CPHI Worldwide and Arab Health.
- •
To meet the growing working capital requirements of the company arising from the expanding scale of business operations.
- •
To fund general corporate purposes, which may include strategic initiatives, and to meet various unforeseen business expenses.
Key Performance Indicator
P/E Ratio
9.27
EPS
13.38
ROE
18.11%
ROCE
16.68%
RONW
16.61%
Debt to Equity Ratio
—
PAT Margin
16.49%
EBITDA Margin
17.73%
P/B
2.19
SWOT Analysis
Strengths
- •
GDP-certified distributor and trader, ensuring compliance with Good Distribution Practices which strengthens credibility with global partners.
- •
Strong global export network supplying specialty drugs, orphan drugs, vaccines, and branded generics to over 35 countries.
- •
Offers a wide and diversified range of both registered and unregistered specialty pharmaceutical products across multiple therapeutic areas.
- •
Ensures quality and traceability by sourcing exclusively from WHO-GMP & ISO 9001-certified manufacturers.
Weaknesses
- •
Limited in-house manufacturing presence, operating primarily as a trading and distribution business, leading to potential margin pressure and lack of control over product sourcing.
- •
Nascent brand visibility as a privately held distributor, lacking the strong brand presence of larger, publicly listed pharmaceutical companies.
- •
Geographic concentration with limited warehousing capabilities may constrain broader and more efficient distribution reach.
- •
Significant dependence on a few major customers for a substantial portion of revenue, posing a risk if these key clients reduce their orders.
Opportunities
- •
Capitalize on the rising global demand for specialty drugs, particularly in oncology, biologics, and rare-disease medications.
- •
Expand into new and underserved geographies, with significant growth potential in markets across Africa, Latin America, and the Middle East.
- •
Forge institutional tie-ups for bulk supply opportunities in NGO programs, clinical trials, and large hospital networks.
- •
Introduce value-added services like pharmacovigilance support, compliance consulting, and specialized cold-chain distribution to deepen client integration.
Threats
- •
Intensifying competition from large, well-capitalized distributors that can leverage greater scale, infrastructure, and more extensive product portfolios.
- •
Vulnerability to global supply-chain disruptions, including API shortages and logistics delays, due to dependency on imported specialty drugs.
- •
Potential for margin compression due to stringent government price controls implemented by authorities like the NPPA on specialty drug categories.
- •
Risk of technology obsolescence if the company fails to make timely investments in modern ERP systems, inventory tracking, and digital compliance tools.
Subscription Rate
Frequently Asked Questions about Speciality Medicines Ltd...
Speciality Medicines Limited is engaged in the marketing and distribution of finished specialty pharmaceutical products. The company focuses on high-cost oral and injectable medications for complex and chronic conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. It operates through a dual business model: contract manufacturing of approved formulations for international distribution, and sourcing from manufacturers for marketing and distribution in domestic and international markets. Its diverse product portfolio includes various dosage forms such as tablets, capsules, injections, and syrups.
The Speciality Medicines Ltd... IPO is scheduled to open for subscription on Mar 20, 2026 and close on Mar 24, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Speciality Medicines Ltd... IPO is ₹117 to ₹124. Investors can place bids within this range once the issue opens.
The minimum lot size for the Speciality Medicines Ltd... IPO is 1000 shares. The minimum investment amount ₹1,24,000.
The total issue size of the Speciality Medicines Ltd... IPO is will be disclosed closer to the issue opening. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Speciality Medicines Ltd... IPO has been subscribed 2.27 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Speciality Medicines Ltd... IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Speciality Medicines Ltd... are expected to list on stock exchanges on Mar 30, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Speciality Medicines Ltd... IPO are proposed to be used for Our Company proposes to utilize the Net Proceeds from the Issue towards funding the following objects:, Setting up a Research and Development (R&D) Centre in Valsad, Gujarat, to internalize formulation development, reduce reliance on third-party manufacturers, develop differentiated dosage forms, and shorten time-to-market for new products., Financing product registration in various international markets such as Ethiopia, Namibia, Jordan, and the Philippines, and funding product development and bioequivalence studies to expand presence in LATAM, Africa, and EMA markets., Funding marketing and promotional activities to enhance brand visibility, strengthen brand equity, and support sales growth across existing and emerging markets, including participation in global pharmaceutical exhibitions like CPHI Worldwide and Arab Health., To meet the growing working capital requirements of the company arising from the expanding scale of business operations., To fund general corporate purposes, which may include strategic initiatives, and to meet various unforeseen business expenses.
Before applying for the Speciality Medicines Ltd... IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
